istock-513551088-handshake
solidcolours / iStockphoto.com
10 May 2017Americas

Sandoz enters agreement to develop non-opioid pain relief

Sandoz has entered into a development and commercialisation agreement with pharmaceutical company Durect to develop the drug Posimir (Saber-bupivacaine).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
22 January 2018   Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.

More on this story

Asia
22 January 2018   Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.

More on this story

Asia
22 January 2018   Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.